Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 18c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $32.83 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Carvana (CVNA) PT Lowered to $85 at RBC Capital